Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03249584 · ClinicalTrials.gov registry record · NA
OsteoCool Tumor Ablation Post-Market Study
A NA study of Metastasis Spine and Metastasis to Bone, sponsored by MedtronicNeuro.
- Completed
- Registry status
- NA
- Development phase
- 218
- Enrollment target
- 16
- Study locations
NCT03249584: Completed NA study of Metastasis Spine and Metastasis to Bone, sponsored by MedtronicNeuro.
NCT03249584 is a NA study of Metastasis Spine and Metastasis to Bone that has completed, run by MedtronicNeuro. The registered enrollment target is 218 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). The trial reports 16 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03249584, a NA study of Metastasis Spine and Metastasis to Bone, has completed, sponsored by MedtronicNeuro.
- COMPLETED
- Registry status
- NA
- Development phase
- 218 participants
- Enrollment target
- 16
- Study locations
Study Summary
This study evaluates the effectiveness of the Medtronic OsteoCool™ RF Ablation System.
Primary Outcome
Demonstrate an improvement of worst pain score (WPS) at the target treatment site in the previous 24 hours for subjects with metastatic lesions in only the thoracic and/or lumbar vertebral body(ies) as collected using the Brief Pain Inventory (BPI). The WPS is a single question from the BPI (scored from 0-10; 0=NO PAIN and 10=PAIN AS BAD AS YOU CAN IMAGINE). Lower scores indicate less pain.
Conditions Studied
Interventions
- DEVICE OsteoCool™ RF Ablation
Study Locations (16)
Other
- Sunnybrook Health Science Centre - Toronto
- Hôpitaux Universitaires de Strasbourg - Nouvel Hôpital Civil - Strasbourg
- Universitätsklinikum Leipzig AöR - Leipzig
- Centre Hospitalier de Luxembourg - Luxembourg
Georgia
- Emory University School of Medicine - Atlanta
- Northside Hospital - Cumming
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
- Duke University Medical Center - Durham
Arizona
- Banner - University Medical Center Phoenix - Phoenix
California
- Saint Jude Medical Center - Fullerton
Florida
- Moffitt Cancer Center - Tampa
Massachusetts
- University of Massachusetts Memorial Medical Center - Worcester
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2017-10-12 |
| Est. Completion | 2020-07-17 |
| Phase | NA |
What the finished NCT03249584 record still lists
NCT03249584 is an interventional study that assigns participants to a tested intervention. The registered 218 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).
The record links to 2 conditions, with Metastasis Spine appearing as the primary indexed condition, and to 1 intervention - of which OsteoCool™ RF Ablation is the first listed.
NCT03249584 lists 16 locations in 11 states (Other, Georgia, North Carolina).
Frequently Asked Questions
What is clinical trial NCT03249584 about?
NCT03249584 is a clinical study titled "OsteoCool Tumor Ablation Post-Market Study". This study evaluates the effectiveness of the Medtronic OsteoCool™ RF Ablation System.
What is the current status of trial NCT03249584?
This trial is currently completed. It is a NA study. The enrollment target is 218 participants. The study started on 2017-10-12. Estimated completion is 2020-07-17.
What conditions does trial NCT03249584 study?
This clinical trial studies the following conditions: Metastasis Spine, Metastasis to Bone.
What interventions are being tested in trial NCT03249584?
The interventions under investigation include: OsteoCool™ RF Ablation (DEVICE).
Who is sponsoring clinical trial NCT03249584?
This trial is sponsored by MedtronicNeuro, which has 51 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03249584 being conducted?
This trial has 16 study locations across Arizona, California, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastasis Spine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03249584's enrollment target sits among peer trials
218 485th of 2000 higher than 1,516 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04693858 · 218 participants · NA
Efficacy Trial of the CALM Intervention
- NCT05909202 · 218 participants · NA
A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
- NCT06000761 · 218 participants · NA
Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit
- NCT06249126 · 218 participants · NA
Primary Subtalar Arthrodesis for Calcaneal Fractures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI